Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients

por Pettersson, Olof, Fröss-Baron, Katarzyna, Crona, Joakim, Sundin, Anders
Publicado 2020

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with (177)Lu-DOTATATE

por Pettersson, Olof Joakim, Fröss-Baron, Katarzyna, Crona, Joakim, Sundin, Anders
Publicado 2021

Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

por Sandström, Mattias, Freedman, Nanette, Fröss-Baron, Katarzyna, Kahn, Tanweera, Sundin, Anders
Publicado 2020

Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by (68)Ga-DOTA...

por Jahn, Ulrika, Ilan, Ezgi, Velikyan, Irina, Fröss-Baron, Katarzyna, Lubberink, Mark, Sundin, Anders
Publicado 2021

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE

por Vyakaranam, Achyut Ram, Crona, Joakim, Norlén, Olov, Granberg, Dan, Garske-Román, Ulrike, Sandström, Mattias, Fröss-Baron, Katarzyna, Thiis-Evensen, Espen, Hellman, Per, Sundin, Anders
Publicado 2019

Prospective observational study of (177)Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-g...

por Garske-Román, Ulrike, Sandström, Mattias, Fröss Baron, Katarzyna, Lundin, Lars, Hellman, Per, Welin, Staffan, Johansson, Silvia, Khan, Tanweera, Lundqvist, Hans, Eriksson, Barbro, Sundin, Anders, Granberg, Dan
Publicado 2018